1 Sep 2020 07:00
Silence Therapeutics Notice of Results
1 September 2020
LONDON, Silence Therapeutics plc (LON: SLN) ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, will announce its unaudited interim results for the half year ended 30 June 2020, on 14 September 2020.
Iain Ross, Executive Chairman, Dr. Rob Quinn, Chief Financial Officer and Dr. Giles Campion, Head of R&D and Chief Medical Officer will host a webcast and live conference call for analysts and investors at 13:00 BST | 08:00 ET on the day of the results.
Details of the webcast and conference call:
Webcast link: https://edge.media-server.com/mmc/p/8yn44oft
Dial-in Details:
United Kingdom 08002796619
United States 18778709135
Conference ID 7577462
For more information, please contact:
Silence Therapeutics plc Iain Ross, Executive Chairman Rob Quinn, Chief Financial Officer
| Tel: +44 (0)20 3457 6900 |
Investec (Nominated Adviser and Broker) Daniel Adams/Gary Clarence
| Tel: +44 (0) 20 7597 5970 |
European IR Consilium Strategic Communications Mary-Jane Elliott/Chris Welsh/Angela Gray silencetherapeutics@consilium-comms.com
| Tel: +44 (0) 20 3709 5700 |
U.S. IR Westwicke Peter Vozzo peter.vozzo@westwicke.com | Tel: +1 (443) 213-0505 |
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-associated proteins. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. The Company has secured high value research and collaboration agreements with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/
SLN.L (SLN)